Several new treatments are transforming glucose care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as leading choices. Retatrutide, a twin GIP and GLP-1 target agonist, demonstrates remarkable body mass decrease and enhanced blood sugar regulation. Cagrillintide, another GLP-1 activator, is now in research studies, indi… Read More